Radius announces positive phase 3 topline results for tymlos® (abaloparatide) subcutaneous injection in males with osteoporosis

Boston, oct. 18, 2021 (globe newswire) -- radius health, inc. (“radius” or the “company”) (nasdaq: rdus), today announced positive topline results from the atom study evaluating abaloparatide 80mcg subcutaneous (sc) for use in males with osteoporosis.

RDUS Ratings Summary

RDUS Quant Ranking